Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Pharmacokinetic Study of Single and Multiple Intravenous Administration of Nalbuphine Hydrochloride Injection in Healthy Chinese Volunteers

NCT06902103 is registered in ClinicalTrials.gov with Yangtze River Pharmaceutical Group Jiangsu Zilong Pharmaceutical Co. Ltd as lead sponsor.

NCT NCT06902103
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06902103 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Pharmacokinetic Study of Single and Multiple Intravenous Administration of Nalbuphine Hydrochloride Injection in Healthy Chinese Volunteers
Lead sponsor
Yangtze River Pharmaceutical Group Jiangsu Zilong Pharmaceutical Co. Ltd
Phase
Phase 1
Overall status
Completed
Start date
December 20, 2023
Completion date
January 18, 2024
Enrollment
22 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

pain